{
    "xml": "<topic id=\"PHP2307\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/fluphenazine-decanoate\" basename=\"fluphenazine-decanoate\" title=\"FLUPHENAZINE DECANOATE\">\n<title>FLUPHENAZINE DECANOATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_380\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/fluphenazine\">Fluphenazine</xref>\n</p>\n<data name=\"vtmid\">321669003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_716774613\" title=\"Antipsychotics (first-generation, depot injections)\">Antipsychotics (first-generation, depot injections)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP59511\" outputclass=\"indicationsAndDose\" rev=\"1.16\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Maintenance in schizophrenia and other psychoses</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Test dose 12.5&#8239;mg, dose to be administered into the gluteal muscle, then 12.5&#8211;100&#8239;mg after 4&#8211;7&#8239;days, then 12.5&#8211;100&#8239;mg every 14&#8211;35&#8239;days, adjusted according to response.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Elderly</p>\n<p>Test dose 6.25&#8239;mg, dose to be administered into the gluteal muscle, then 12.5&#8211;100&#8239;mg after 4&#8211;7&#8239;days, then 12.5&#8211;100&#8239;mg every 14&#8211;35&#8239;days, adjusted according to response.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59542\" outputclass=\"contraindications\" rev=\"1.13\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Children</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">marked cerebral atherosclerosis</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59551\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">QT-interval prolongation</ph>; <ph outputclass=\"caution\">when transferring from oral to depot therapy, the dose by mouth should be reduced gradually</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59505\" outputclass=\"interactions\" rev=\"1.14\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Avoid concomitant drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59458\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Erythema</ph>; <ph outputclass=\"sideEffect\">inappropriate antidiuretic hormone secretion</ph>; <ph outputclass=\"sideEffect\">nodules</ph>; <ph outputclass=\"sideEffect\">oedema</ph>; <ph outputclass=\"sideEffect\">pain at injection site</ph>; <ph outputclass=\"sideEffect\">swelling</ph>; <ph outputclass=\"sideEffect\">systemic lupus erythematosus</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>Less sedating and fewer antimuscarinic or hypotensive symptoms, but extrapyramidal symptoms, particularly dystonic reactions and akathisia, more frequent. Extrapyramidal symptoms usually appear a few hours after injection and continue for about 2 days but may be delayed.</p>\n</sectiondiv>\n<sectiondiv>\n<p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59500\" outputclass=\"pregnancy\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59556\" outputclass=\"breastFeeding\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. <i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n<p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59520\" outputclass=\"hepaticImpairment\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in hepatic failure.</p>\n<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59481\" outputclass=\"renalImpairment\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution.</p>\n<p>Avoid in renal failure.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59402\" outputclass=\"monitoringRequirements\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Treatment requires careful monitoring for optimum effect.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59578\" outputclass=\"directionsForAdministration\" rev=\"1.11\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>In general not more than 2&#8211;3&#8239;mL of oily injection should be administered at any one site.</p>\n<p>Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.</p>\n<p>When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2307-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/fluphenazine-decanoate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77878\" title=\"Solution for injection\" namespace=\"/drugs/fluphenazine-decanoate/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"3\" rel=\"backlink\">Psychoses and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_380\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/fluphenazine\" title=\"Fluphenazine\" count=\"1\" rel=\"link\">Fluphenazine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77878\" namespace=\"/drugs/fluphenazine-decanoate/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2307",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/fluphenazine-decanoate",
    "basename": "fluphenazine-decanoate",
    "title": "FLUPHENAZINE DECANOATE",
    "interactants": [
        {
            "id": "bnf_int_380",
            "label": "Fluphenazine"
        }
    ],
    "vtmid": "321669003",
    "drugClassification": [
        "Antipsychotics (first-generation, depot injections)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Maintenance in schizophrenia and other psychoses",
                        "html": "Maintenance in schizophrenia and other psychoses"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Test dose 12.5 mg, dose to be administered into the gluteal muscle, then 12.5&#8211;100 mg after 4&#8211;7 days, then 12.5&#8211;100 mg every 14&#8211;35 days, adjusted according to response.",
                        "html": "<p>Test dose 12.5&#8239;mg, dose to be administered into the gluteal muscle, then 12.5&#8211;100&#8239;mg after 4&#8211;7&#8239;days, then 12.5&#8211;100&#8239;mg every 14&#8211;35&#8239;days, adjusted according to response.</p>"
                    },
                    {
                        "textContent": "Test dose 6.25 mg, dose to be administered into the gluteal muscle, then 12.5&#8211;100 mg after 4&#8211;7 days, then 12.5&#8211;100 mg every 14&#8211;35 days, adjusted according to response.",
                        "html": "<p>Test dose 6.25&#8239;mg, dose to be administered into the gluteal muscle, then 12.5&#8211;100&#8239;mg after 4&#8211;7&#8239;days, then 12.5&#8211;100&#8239;mg every 14&#8211;35&#8239;days, adjusted according to response.</p>",
                        "ageGroup": "elderly"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose adjustment may be necessary if smoking started or stopped during treatment.",
                "html": "<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Children",
                "html": "Children"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "marked cerebral atherosclerosis",
                "html": "marked cerebral atherosclerosis"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "QT-interval prolongation",
                "html": "QT-interval prolongation"
            },
            {
                "type": "cautions",
                "textContent": "when transferring from oral to depot therapy, the dose by mouth should be reduced gradually",
                "html": "when transferring from oral to depot therapy, the dose by mouth should be reduced gradually"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Avoid concomitant drugs that prolong QT interval.",
                "html": "<p>Avoid concomitant drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Erythema",
                        "html": "Erythema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "inappropriate antidiuretic hormone secretion",
                        "html": "inappropriate antidiuretic hormone secretion",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nodules",
                        "html": "nodules",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pain at injection site",
                        "html": "pain at injection site",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "swelling",
                        "html": "swelling",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "systemic lupus erythematosus",
                        "html": "systemic lupus erythematosus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "Less sedating and fewer antimuscarinic or hypotensive symptoms, but extrapyramidal symptoms, particularly dystonic reactions and akathisia, more frequent. Extrapyramidal symptoms usually appear a few hours after injection and continue for about 2 days but may be delayed.",
                "html": "<p>Less sedating and fewer antimuscarinic or hypotensive symptoms, but extrapyramidal symptoms, particularly dystonic reactions and akathisia, more frequent. Extrapyramidal symptoms usually appear a few hours after injection and continue for about 2 days but may be delayed.</p>"
            },
            {
                "type": "advice",
                "textContent": "If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.",
                "html": "<p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.\n\nPhenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. <i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p><p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in hepatic failure.\n\nCan precipitate coma; phenothiazines are hepatotoxic.",
                "html": "<p>Avoid in hepatic failure.</p><p>Can precipitate coma; phenothiazines are hepatotoxic.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution.\n\nAvoid in renal failure.",
                "html": "<p>Manufacturer advises caution.</p><p>Avoid in renal failure.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Treatment requires careful monitoring for optimum effect.",
                "html": "<p>Treatment requires careful monitoring for optimum effect.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "In general not more than 2&#8211;3 mL of oily injection should be administered at any one site.\n\nCorrect injection technique (including use of z-track technique) and rotation of injection sites are essential.\n\nWhen initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.",
                "html": "<p>In general not more than 2&#8211;3&#8239;mL of oily injection should be administered at any one site.</p><p>Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.</p><p>When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77878",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_380",
                "label": "Fluphenazine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77878",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}